Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 28;28(17):3890–3901. doi: 10.1158/1078-0432.CCR-22-0569

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 5. Levels of EV-GPX3 and EV-ACTR3 and corresponding protein expression in HCC and ALT prior to SIRT+sorafenib treatment (A–D) and sorafenib treatment (E–H) in responders (R) and nonresponders (NR). A, Correlation analysis of EV-GPX3 and EV-ACTR3 showing distinct clusters of responders and nonresponders in the SIRT+sorafenib treatment group. B, Representative images of hematoxylin and eosin (H&E) staining of HCC tissue and ALT prior to SIRT+sorafenib treatment. C, IHC staining of GPX3 in HCC tissue and ALT prior to SIRT+sorafenib treatment. D, IHC staining of ACTR3 in HCC tissue and ALT prior to SIRT+sorafenib treatment. E, Correlation analysis of EV-GPX3 and EV-ACTR3 in sorafenib treatment group. F, Representative images of H&E staining of HCC tissue and ALT prior to sorafenib treatment. G, IHC staining of GPX3 in HCC tissue and ALT prior to sorafenib treatment. H, IHC staining of ACTR3 in HCC tissue and ALT prior to sorafenib treatment. Magnification: 400×; scale bar: 50 μm. — Levels of EV-GPX3 and EV-ACTR3 and corresponding protein expression in HCC and ALT prior to SIRT+sorafenib treatment (A–D) and sorafenib treatment (E–H) in responders (R) and nonresponders (NR). A, Correlation analysis of EV-GPX3 and EV-ACTR3 showing distinct clusters of responders and nonresponders in the SIRT+sorafenib treatment group. B, Representative images of hematoxylin and eosin (H&E) staining of HCC tissue and ALT prior to SIRT+sorafenib treatment. C, IHC staining of GPX3 in HCC tissue and ALT prior to SIRT+sorafenib treatment. D, IHC staining of ACTR3 in HCC tissue and ALT prior to SIRT+sorafenib treatment. E, Correlation analysis of EV-GPX3 and EV-ACTR3 in sorafenib treatment group. F, Representative images of H&E staining of HCC tissue and ALT prior to sorafenib treatment. G, IHC staining of GPX3 in HCC tissue and ALT prior to sorafenib treatment. H, IHC staining of ACTR3 in HCC tissue and ALT prior to sorafenib treatment. Magnification: 400×; scale bar: 50 μm.